Detalles de la búsqueda
1.
Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial.
Clin Chem;
70(1): 307-318, 2024 01 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38175595
2.
Dietary supplement intake in women with breast cancer before and after diagnosis: results from the SUCCESS C trial.
BMC Cancer;
24(1): 591, 2024 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38750410
3.
Effect of histological breast cancer subtypes invasive lobular versus non-special type on survival in early intermediate-to-high-risk breast carcinoma: results from the SUCCESS trials.
Breast Cancer Res;
25(1): 153, 2023 12 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38098086
4.
Evaluating ChatGPT as an adjunct for the multidisciplinary tumor board decision-making in primary breast cancer cases.
Arch Gynecol Obstet;
308(6): 1831-1844, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37458761
5.
The Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer Centers.
Int J Mol Sci;
24(22)2023 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38003555
6.
The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C.
Br J Cancer;
126(12): 1715-1724, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35194193
7.
Early dissemination seeds metastasis in breast cancer.
Nature;
540(7634): 552-558, 2016 Dec 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-27974799
8.
Interleukin 15 and Eotaxin correlate with the outcome of breast cancer patients vice versa independent of CTC status.
Arch Gynecol Obstet;
303(1): 217-230, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32929618
9.
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial.
Breast Cancer Res;
22(1): 111, 2020 10 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-33097092
10.
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial.
Int J Cancer;
145(3): 857-868, 2019 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30694523
11.
Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients.
Int J Cancer;
145(8): 2114-2121, 2019 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30901076
12.
Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial.
Breast Cancer Res Treat;
175(3): 627-635, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30900137
13.
Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer.
Breast Cancer Res Treat;
174(2): 453-461, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30603996
14.
The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer.
Breast Cancer Res Treat;
172(1): 93-104, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30003393
15.
Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment.
Breast Cancer Res Treat;
171(3): 571-580, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-29931425
16.
Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients.
BMC Cancer;
18(1): 141, 2018 02 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29409452
17.
Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.
BMC Cancer;
18(1): 541, 2018 May 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29739347
18.
Biologic meshes and synthetic meshes in cancer patients: a double-edged sword: differences in production of IL-6 and IL-12 caused by acellular dermal matrices in human immune cells.
Arch Gynecol Obstet;
297(5): 1265-1270, 2018 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-29417284
19.
Fluorescence Analysis of Vitamin D Receptor Status of Circulating Tumor Cells (CTCS) in Breast Cancer: From Cell Models to Metastatic Patients.
Int J Mol Sci;
18(6)2017 Jun 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-28632174
20.
CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients.
Tumour Biol;
37(10): 13769-13775, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27481512